Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

AI will inevitably bring revolutionary benefits to pharma, but the transformation will be more gradual and nuanced than in ...

Bristol Myers Squibb is doubling down on a partnership with Medidata, signing a multiyear agreement to continue using the ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.